摘要目的:探讨DNA甲基转移酶3A(DNMT3A)、MAX基因关联蛋白A(MGA)、磷酯酰肌醇-3激酶催化亚基γ基因(PIK3CG)基因突变与老年非小细胞肺癌患者预后的关系。方法:选择2014年3月至2017年3月收治的468例非小细胞肺癌患者，采用扩增阻滞突变系统(ARMS)检测其癌组织中DNMT3A、MGA、PIK3CG基因突变，分析DNMT3A、MGA、PIK3CG基因突变与临床病理特征及预后的相关性。结果:468例非小细胞肺癌患者中，DNMT3A基因突变阳性37例(7.91%)，MGA基因突变阳性25例(5.34%)，PIK3CG基因突变阳性19例(4.06%)；年龄、性别、吸烟情况、肿瘤直径、病理类型不同的非小细胞肺癌患者DNMT3A、MGA、PIK3CG基因突变率差异无统计学意义( P>0.05)；淋巴结转移、临床分期不同的非小细胞肺癌患者DNMT3A、MGA、PIK3CG基因突变率差异有统计学意义( P<0.05)；DNMT3A、MGA、PIK3CG基因突变阳性的非小细胞肺癌患者OS、PFS显著低于DNMT3A、MGA、PIK3CG基因突变阴性的非小细胞肺癌患者( P<0.05)。 结论:DNMT3A、MGA、PIK3CG基因突变与老年非小细胞肺癌患者淋巴结转移、临床分期及预后明显相关，发生淋巴结转移、临床分期较高、预后较差的老年非小细胞肺癌患者DNMT3A、MGA、PIK3CG基因突变率越高。

abstractsObjective:To investigate the relationship between DNA methyltransferase 3A (DNMT3A), MAX gene-associated protein (MGA), phosphoinositide-3 kinase catalytic subunit gamma (PIK3CG) gene mutations and the prognosis of elderly patients with non-small cell lung cancer.Methods:468 patients with non-small cell lung cancer from March 2014 to March 2017 were enrolled. Amplification refractory mutation system (ARMS) was used to detect the mutations of DNMT3A, MGA and PIK3CG genes in cancer tissue. Then the correlation between DNMT3A, MGA, PIK3CG gene mutations and clinicopathological characteristics and prognosis was also determined.Results:Among the 468 patients with NSCLC, 37 (7.91%) cases had DNMT3A gene mutation, 25 (5.34%) cases had MGA gene mutation, and 19 (4.06%) cases had PIK3CG gene mutation. The mutation rates of DNMT3A, MGA and PIK3CG had no difference among patients with different age, gender, smoking status, tumor diameter and pathological types ( P>0.05), while had significant difference among patients with different lymph node metastasis status and different clinical stages ( P<0.05). OS and PFS in NSCLC patients with DNMT3A, MGA and PIK3CG gene mutation were significantly lower than those without DNMT3A, MGA and PIK3CG gene mutations ( P<0.05). Conclusion:DNMT3A, MGA, PIK3CG gene mutations are related to lymph node metastasis, clinical stage and prognosis in elderly patients with non-small cell lung cancer, moreover, patients with lymph node metastasis, high clinical stage and poor prognosis have high mutation rates of DNMT3A, MGA and PIK3CG, which can provide reference for clinical treatment of elderly patients with non-small cell lung cancer.